Roger Jeffs Sells 14,130 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 14,130 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the transaction, the chief executive officer now owns 1,006,420 shares of the company’s stock, valued at approximately $13,657,119.40. The trade was a 1.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Liquidia Price Performance

LQDA stock opened at $13.72 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -8.42 and a beta of 0.23. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $16.81. The business has a fifty day moving average price of $14.70 and a 200-day moving average price of $12.76.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million during the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, analysts anticipate that Liquidia Co. will post -1.51 earnings per share for the current year.

Analyst Ratings Changes

LQDA has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank reiterated an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 target price on shares of Liquidia in a report on Thursday, April 10th. Finally, Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $26.63.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Liquidia by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock valued at $41,834,000 after buying an additional 115,367 shares during the last quarter. LM Advisors LLC bought a new stake in shares of Liquidia in the fourth quarter worth $25,948,000. Whitefort Capital Management LP increased its position in Liquidia by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock valued at $23,370,000 after acquiring an additional 285,220 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Liquidia by 17.3% in the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company’s stock valued at $20,698,000 after acquiring an additional 260,000 shares during the period. Finally, Geode Capital Management LLC boosted its position in Liquidia by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock worth $15,753,000 after purchasing an additional 101,597 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).